Parkinson's disease: integrated multidisciplinary care


Sudden unexpected death in epilepsy ( SUDEP ) is the leading cause of death in people with chronic refractory epilepsy. Very rarely, SUDEP occurs in epilepsy monitoring units, providing highly informative data for its still elusive pathophysiology.
The MORTEMUS study expanded these data through comprehensive evaluation of cardiorespiratory arrests encountered in epilepsy monitoring units worldwide.

During the period 2008-2009, researchers did a systematic retrospective survey of epilepsy monitoring units located in Europe, Israel, Australia, and New Zealand, to retrieve data for all cardiorespiratory arrests recorded in these units and estimate their incidence.
Epilepsy monitoring units from other regions were invited to report similar cases to further explore the mechanisms.
An expert panel reviewed data, including video electroencephalogram ( VEEG ) and electrocardiogram material at the time of cardiorespiratory arrests whenever available.

A total of 147 ( 92% ) of 160 units responded to the survey; 29 cardiorespiratory arrests, including 16 sudden unexpected death in epilepsy ( 14 at night ), nine near SUDEP, and four deaths from other causes, were reported.

Cardiorespiratory data, available for ten cases of SUDEP, showed a consistent and previously unrecognised pattern whereby rapid breathing ( 18-50 breaths per min ) developed after secondary generalised tonic-clonic seizure, followed within 3 min by transient or terminal cardiorespiratory dysfunction.
Where transient, this dysfunction later recurred with terminal apnoea occurring within 11 min of the end of the seizure, followed by cardiac arrest.

SUDEP incidence in adult epilepsy monitoring units was 5.1 per 1000 patient-years, with a risk of 1.2 per 10000 VEEG monitorings, probably aggravated by suboptimum supervision and possibly by antiepileptic drug withdrawal.

The study revealed that SUDEP in epilepsy monitoring units primarily follows an early postictal, centrally mediated, severe alteration of respiratory and cardiac function induced by generalised tonic-clonic seizure, leading to immediate death or a short period of partly restored cardiorespiratory function followed by terminal apnoea then cardiac arrest. ( Xagena )

Ryvlin P et al, The Lancet Neurology 2013; 12: 966-977

XagenaMedicine_2013



Indietro

Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved XCopri ( Cenobamate tablets ) to treat partial-onset seizures...


The FDA ( U.S. Food and Drug Administration ) has approved Xcopri ( Cenobamate tablets ) to treat partial-onset seizures...


The positive results of the first pivotal phase 3 study of the investigational medicine Epidiolex ( Cannabidiol or CBD )...


The aim of a study was to evaluate the efficacy and safety of the new antiepileptic drug Brivaracetam ( Briviact...


Brivaracetam ( UCB 34714; Briviact ) is an add-on treatment for adult patients with partial seizures. Similar to Levetiracetam (...


In February 2014, the American Heart Association [ AHA ] /American Stroke Association [ ASA ] released their first guideline...


Preliminary efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with an...


A phase III clinical trial ( Study 332 ) of AMPA receptor antagonist Perampanel ( Fycompa ) has met its...


A study ( Study 307 ) has evaluated safety, tolerability, seizure frequency, and regional variations in treatment responses with the...


Sudden unexpected death in epilepsy ( SUDEP ) is the leading cause of death in people with chronic refractory epilepsy....